1.2 Cashless Exercise. At any time after a Change of Control ----------------- (as defined herein) but prior to the Expiration Date, in lieu of the payment of the Exercise Price, the Warrantholder shall have the right (but not the obligation) to...Viropharma Inc • May 14th, 1999 • Pharmaceutical preparations • New York
W I T N E S E T H: - - - - - - - - -Consulting Agreement • November 12th, 1997 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
andRights Agreement • September 21st, 1998 • Viropharma Inc • Pharmaceutical preparations • Delaware
EXHIBIT 1 2,250,000 Shares VIROPHARMA INCORPORATED COMMON STOCK UNDERWRITING AGREEMENT ---------------------- November __, 1996 COWEN & COMPANY J.P. MORGAN SECURITIES INC. As Representatives of the several Underwriters c/o Cowen & Company Financial...Underwriting Agreement • November 8th, 1996 • Viropharma Inc • Pharmaceutical preparations • New York
EXHIBIT 4.2 AMENDMENT NO. 1 TO RIGHTS AGREEMENT ----------------------------------- AMENDMENT, dated as of May 5, 1999, to the Rights Agreement, dated as of September 10, 1996 (the "Rights Agreement"), between ViroPharma Incorporated, a Delaware...Rights Agreement • May 14th, 1999 • Viropharma Inc • Pharmaceutical preparations
Exhibit 1.1 UNDERWRITING AGREEMENT VIROPHARMA INCORPORATED 2,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • July 11th, 1997 • Viropharma Inc • Pharmaceutical preparations • New York
BETWEENLease Agreement • November 13th, 2001 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
EXHIBIT 10.27 Portions of this exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of...Viropharma Inc • May 11th, 2000 • Pharmaceutical preparations • New York
AMONGInvestment Agreement • May 14th, 1999 • Viropharma Inc • Pharmaceutical preparations • New York
CREDIT AGREEMENT dated as of September 9, 2011 among VIROPHARMA INCORPORATED, as Borrower The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent and BMO HARRIS FINANCING INC., TD BANK, N.A. and MORGAN STANLEY BANK, N.A. as...Credit Agreement • October 27th, 2011 • Viropharma Inc • Pharmaceutical preparations • New York
CREDIT AGREEMENT (this “Agreement”) dated as of September 9, 2011 among VIROPHARMA INCORPORATED, the LENDERS from time to time party hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent and BMO HARRIS FINANCING INC., TD BANK, N.A. and MORGAN STANLEY BANK, N.A.,, as Co-Syndication Agents.
To Summit Bank as Trustee INDENTURE Dated as of March 1, 2000Viropharma Inc • May 11th, 2000 • Pharmaceutical preparations • New York
DEVELOPMENT AGREEMENT --------------------- This Agreement is entered into this 16th day of April, 1997, by and between SELOC AG, a corporation organized under the laws of Switzerland with a principal place of business at Industriestrasse 7, 4410...Development Agreement • June 25th, 1997 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
AMENDMENT TO RESTRICTED STOCK PURCHASE AGREEMENT Amendment to Restricted Stock Purchase Agreement dated as of January 17, 1996, among VIROPHARMA, INC., a Delaware corporation (the "Corporation"), and Frank Baldino, Jr. (the "Purchaser"), dated as of...Restricted Stock Purchase Agreement • November 8th, 1996 • Viropharma Inc • Pharmaceutical preparations • Delaware
Section of Trust Indenture Act Section of Of 1939, as Amended Indenture ------------------- ---------- 310(a)................................................. 7.09 310(b)................................................. 7.08...Viropharma Inc • September 12th, 2001 • Pharmaceutical preparations • New York
Exhibit 1.2 4,000,000 Shares VIROPHARMA INCORPORATED COMMON STOCK, $.002 PAR VALUE UNDERWRITING AGREEMENT November 14, 2001Viropharma Inc • November 15th, 2001 • Pharmaceutical preparations • New York
RECITALSStock Purchase Agreement • May 11th, 2001 • Viropharma Inc • Pharmaceutical preparations • Delaware
ViroPharma Incorporated $225,000,000 2.00% Convertible Senior Notes Due 2017Underwriting Agreement • March 26th, 2007 • Viropharma Inc • Pharmaceutical preparations • New York
ViroPharma Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $225,000,000 principal amount of the 2.00% Convertible Senior Notes due 2017, convertible into shares of Common Stock, par value $0.002 per share (the “Stock”) of the Company specified above (the “Firm Securities”) and, at the election of the Underwriters, up to an aggregate of $25,000,000 additional aggregate principal amount of such Convertible Senior Notes (the “Optional Securities”) (the Firm Securities and the Optional Securities which the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”).
Exhibit 10.20 FIRST AMENDMENT TO AGREEMENT This FIRST AMENDMENT TO AGREEMENT (this "Amendment") is made this 21st day of February, 1997, between ViroPharma Incorporated (formerly ViroPharma, Inc.), a Delaware corporation ("VP"), having its principal...To Agreement • June 25th, 1997 • Viropharma Inc • Pharmaceutical preparations
EXHIBIT 10.34 PORTIONS OF THIS EXHIBIT WERE OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE...Manufacturing Agreement • August 10th, 2001 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
RECITALSStock Purchase Agreement • March 15th, 2000 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
EXHIBIT 10.29 PROMISSORY NOTE ---------------Viropharma Inc • November 12th, 1997 • Pharmaceutical preparations • Pennsylvania
Exhibit 10.33 Portions of this exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of...Collaboration and License Agreement • August 14th, 2003 • Viropharma Inc • Pharmaceutical preparations • New Jersey
EXHIBIT 10.25 ESCROW AGREEMENT ---------------- This Escrow Agreement ("Agreement") is made this 21st day of July 1997 by and between THE HANKIN GROUP, a Pennsylvania partnership ("Landlord"), VIROPHARMA, INC. ("Tenant"), and MANITO ABSTRACT COMPANY,...Escrow Agreement • July 22nd, 1997 • Viropharma Inc • Pharmaceutical preparations
ATViropharma Inc • July 22nd, 1997 • Pharmaceutical preparations
Exhibit 10.28 REGISTRATION RIGHTS AGREEMENT by and among VIROPHARMA INCORPORATEDRegistration Rights Agreement • May 11th, 2000 • Viropharma Inc • Pharmaceutical preparations • New York
6. RELATIONSHIP BETWEEN PARTIES. Consultant will be retained by the Company ---------------------------- strictly for the purposes and to the extent set forth in this Agreement and his relationship to the Company shall be that of an independent...Consulting Agreement • March 27th, 1998 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
EXHIBIT 10.7 COLLABORATIVE RESEARCH AGREEMENT * THIS COLLABORATIVE RESEARCH AGREEMENT is made as of the 23rd day of July 1996, between BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., a Delaware corporation having offices at 900 Ridgebury Road, Ridgefield,...Collaborative Research Agreement • November 14th, 1996 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
RECITALS --------Stock Purchase Agreement • November 13th, 2001 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
Agreement --------- 1. Defined Terms. Capitalized terms not otherwise defined herein ------------- shall have the meaning set forth in the Lease.Purchase Option Agreement • July 22nd, 1997 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
Section of Trust Indenture Act Section of Of 1939, as Amended Indenture ------------------- ---------- 310(a)................................................. 7.09 310(b)................................................. 7.08...Viropharma Inc • July 3rd, 2001 • Pharmaceutical preparations • New York
WITNESSETH: -----------Employee Stock Purchase Agreement • November 8th, 1996 • Viropharma Inc • Pharmaceutical preparations • Delaware
BACKGROUNDCommercialization Agreement • March 15th, 2000 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
CHANGE OF CONTROL AGREEMENTChange of Control Agreement • January 7th, 2011 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
THIS CHANGE OF CONTROL AGREEMENT (this “Agreement”), is made on this 6th day of January, 2010, by and between VIROPHARMA INCORPORATED (the “Company”) and (the “Employee”).
Underwriting AgreementUnderwriting Agreement • December 7th, 2005 • Viropharma Inc • Pharmaceutical preparations • New York
AGREEMENT AND PLAN OF MERGER dated as of November 11, 2013, among SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED, VENUS NEWCO, INC., VIROPHARMA INCORPORATED and SHIRE PLC (solely for the purposes set forth in Section 10.16)Agreement and Plan of Merger • November 12th, 2013 • Viropharma Inc • Pharmaceutical preparations • Delaware
This AGREEMENT AND PLAN OF MERGER, dated as of November 11, 2013 (this “Agreement”), is by and among SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED, a company incorporated in Ireland (“Parent”), VENUS NEWCO, INC., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and VIROPHARMA INCORPORATED, a Delaware corporation (the “Company”), and, solely for the purposes set forth in Section 10.16, SHIRE PLC, a company incorporated in Jersey (“Parent Holdco”).
